Cardiothoracic Surgery Division

Adult

Irving L. Kron, MD
Read Dr. Kron’s Full Bio

Ourania Preventza, MD
Read Dr. Preventza’s Full Bio

Curtis G. Tribble, MD
Read Dr. Tribble’s Full Bio

Leora T. Yarboro, MD
Read Dr. Yarboro’s Full Bio

Kenan W. Yount, MD
Read Dr. Yount’s Full Bio

Congenital

James Gangemi, MD
Read Dr. Gangemi’s Full Bio

Mark E. Roeser, MD
Read Dr. Roeser’s Full Bio

Philip C. Smith, MD
Read Dr. Smith’s Full Bio

Marco G. Patti, MD
Instructor

The Advanced Cardiac Valve Center formally started in 2008 when UVA was the first in Virginia to start performing transcatheter aortic valve replacement (TAVR). Long before that, UVA cardiac surgeons were known in the region as the go-to specialists for valve surgery. Over the last 10 years, UVA cardiac surgeons and cardiologists work closely together to create a personalized approach for every patient. This allows the best possible outcome. UVA has gained international recognition for our Valve Center with a focus on performing complex high risk cases, innovative minimally invasive procedures, and a number of novel transcatheter trials.

The Minimally Invasive Valve Program began in 2012. Currently, both low and high risk patients are eligible to get their valve surgery through less invasive incisions that don’t break the breast bone. In addition, UVA has many novel clinical trials related to valve disease, often being the first to perform procedures in the U.S. Patients often travel from significant distances to be evaluated for less invasive and novel clinical trials. Our aortic valve and mitral valve outcomes have some of the best outcomes in the region, commonly receiving  3 stars (top STS rating) for low mortality and complications.

UVA’s Advanced Heart Failure and Transplant Program is recognized for its expertise throughout the region. UVA has received numerous awards and recognition from the American Heart Association and U.S. News & World Report for outstanding treatment of heart failure. Surgeons and cardiologists with decades of experience lead specialized teams who only focus on treating patients with severe heart failure. UVA’s ventricular assist device (LVAD) program has the most advanced VADs available and participates in numerous clinical trials offering cutting edge therapies. In fact, our LVAD and Transplant program has received numerous accolades for our volume, outcomes, and patient satisfaction scores.

In addition to our heart failure program, UVA’s ECMO team is the only one in Virginia named a Center of Excellence with Gold Status from the Extracorporeal Life Support Organization. In extreme cases of cardiopulmonary failure, UVA can support patients with a special life support machine to act as your heart and lungs and pump blood to the body and vital organs. UVA has developed an ECMO transport system to bring patients who need ECMO to UVA urgently as well as expertise in definitive therapies beyond ECMO which may include LVADs and heart transplantation.

Coronary artery disease remains one of the leading causes of death in Virginia. UVA has long employed a heart team approach to treat patients with complex coronary artery disease combining the expertise of cardiologists and surgeons who specialize in fixing blocked coronary arteries. UVA has received the highest possible rating from the U.S. News & World Report in heart bypass surgery. UVA surgeons can perform standard open CABG procedures often using multiple arteries to perform bypass surgery as well as minimally invasive CABG through without breaking the breast bone. In addition, UVA has been a leader in numerous NIH and industry sponsored trials and is the only in Virginia to offer cutting edge technologies to patients undergoing CABG surgery including hybrid coronary revascularization (combining stents with minimally invasive CABG), and using a special external wrap to help vein bypasses last longer.

UVA has long been a major referral center across the state and region for treating patients with complex aortic disease. Recently UVA has created a comprehensive Complex Aortic Disease Center. Our center provides the full array of treatments to patients with aortic disease including percutaneous endografting, complex open surgery, and hybrid approaches combining the two. UVA has access to many of the cutting edge trials and therapies that are in development, giving patients options that they may not have had before. Furthermore, UVA surgeons have developed many techniques over the years that have been employed by other surgeons across the world. Cardiac surgeons, vascular surgeons, cardiologists, and interventional radiologists all work collaboratively at UVA to provide the best care possible to treat aortic diseases, including congenital and acquired aortic diseases.

Atrial fibrillation is the most common arrhythmia and can result in stroke and death. UVA provides comprehensive care for all aspects of atrial fibrillation. The cardiac surgeons work closely with the cardiologists to tailor a personalized treatment plan for each patient. In some cases this is a catheter-based ablation while in others it is a surgical ablation in conjunction with other cardiac surgery. In some cases a hybrid approach is used with a minimally-invasive surgical ablation followed by catheter-based ablation. UVA cardiac surgeons have extensive experience with surgery to ligate the left atrial appendage, dramatically reducing the risk of stroke. Furthermore, our surgeons were the leaders in placing a novel clip to ligate the appendage that led to FDA approval.

Learn more about ECMO

A unique feature of our division, Dr. Christopher Scott  has developed a comprehensive, team approach to evaluating and treating people who suffer from severe shortness of breath due to chronic pulmonary emboli (blood clots). Very few programs in the country offer this treatment.

Our team of cardiac surgeons and engineers has developed a novel intraventricular stent (VADstent) to prevent suction events and attenuate adverse RV remodeling in patients with continuous flow ventricular assist devices (VAD). The VADstent is deployed during implantation of the inflow cannula and stents the left ventricle open to prevent collapse, keep the septum midline, and align the cannula with the mitral valve. We performed proof of concept studies in swine and ovine models. The VADstent was able to prevent suction events and maintain the geometry of the left ventricle. Importantly, no ventricular arrhythmias, hemolysis, mitral valve injury or other adverse events were noted during these experiments. Currently we have updated our prototype based on previous results and are ready to move into a long-term animal model to assess durability prior to first in human studies.

UVA cardiac surgeons have patented and developed a novel laparoscopic port that allows surgeons to cauterize any bleeding from the abdominal or chest wall by using the port itself. In collaboration with the School of Engineering, early prototypes have been developed and proven effective in early animal studies.

For over two decades, the Kron/Laubach lab has been investigating lung injury as it pertains to ischemia/reperfusion, during lung transplantation, and during cardiopulmonary bypass. Dr. Roeser’s research focuses on innovative technologies to treat ARDS and burn injuries. Dr. Teman’s research interests are in the detection and prevention of organ damage related to cardiopulmonary bypass (the “heart-lung machine”). Collectively, this lab has had numerous grants from the NIH, DOD, and American Heart Association.

Our team at UVA has been highly prolific in investigations that strive for the best possible outcome. Whether it is deciding on which patients benefit the most from an operation, or risk factors for specific complications, our surgeons are constantly trying to provide the best possible care based on up-to-date knowledge. We also work closely with and serve leadership positions in the Virginia Cardiac Surgery Quality Initiation (VCSQI) the largest regional clinical outcomes collaborative in the U.S. targeted at improving cardiac outcomes.